(Bebtelovimab)Biosimilar Reference Antibody-GS40062 新品

货号：GS40062

Bebtelovimab is a fully human, neutralizing monoclonal antibody (IgG1) developed for the treatment of mild-to-moderate COVID-19 in high-risk patients. It was derived from a convalescent donor and specifically engineered to target a highly conserved epitope on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. It potently neutralizes the virus by blocking its attachment to the human ACE2 receptor. Bebtelovimab was notable for maintaining neutralizing activity against the Omicron variant (BA.1, BA.2) and its early sublineages when many earlier antibodies lost efficacy. It received Emergency Use Authorization (EUA) from the U.S. FDA in February 2022. However, as newer Omicron subvariants (particularly BQ.1 and BQ.1.1) emerged and demonstrated significant resistance, its EUA was revoked by the FDA in November 2022, and it is no longer authorized for use in the United States.